Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Abstract

Age, years, median (IQR) 66 (54-74) Cancer location, n (%) Breast 37 (34) Lung 15 (14) Gynecological 15 (14) Prostate 11 (10) Digestive 8 (7.3) Kidney 7 (6.4) Bladder 5 (4.5) Upper aero-digestive tract 6 (5.5) Thyroid 5 (4.5) Others 3 (2.7) Cancer staging, n (%) Local 47 (43) Metastatic 63 (57) Cancer treatment, n (%) Chemotherapy 38 (35) Targeted therapy 26 (24) Immunotherapy 17 (16) Hormonotherapy 16 (15) Radiotherapy 6 (5.5) Clinical surveillance 18 (16) Time between first vaccine injection and SARS-CoV-2 serology, days, median (IQR) 27 (26-28)